FY2024 Earnings Forecast for Nyxoah Issued By HC Wainwright

Nyxoah S.A. (NASDAQ:NYXH) – Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Nyxoah in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst E. White now expects that the company will post earnings of ($2.00) per share for the year, down from their prior estimate of ($1.65). HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Nyxoah’s Q4 2024 earnings at ($0.54) EPS, FY2025 earnings at ($1.28) EPS and FY2026 earnings at $0.44 EPS.

Several other research firms also recently weighed in on NYXH. Oppenheimer decreased their price objective on Nyxoah from $15.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Nyxoah in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nyxoah currently has an average rating of “Buy” and a consensus target price of $17.00.

Nyxoah Stock Down 1.6 %

Shares of NASDAQ NYXH opened at $9.49 on Monday. Nyxoah has a twelve month low of $4.00 and a twelve month high of $20.00. The business has a fifty day simple moving average of $8.97 and a two-hundred day simple moving average of $8.78. The company has a quick ratio of 5.16, a current ratio of 5.28 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Nyxoah

A number of institutional investors have recently added to or reduced their stakes in NYXH. CVI Holdings LLC purchased a new stake in shares of Nyxoah during the second quarter valued at about $1,292,000. Ikarian Capital LLC bought a new position in shares of Nyxoah during the 1st quarter worth approximately $684,000. Kovack Advisors Inc. purchased a new stake in Nyxoah during the third quarter valued at approximately $96,000. Finally, Iron Triangle Partners LP purchased a new stake in Nyxoah during the first quarter valued at approximately $3,413,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.